Loss of NPM2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma: a single-center study of 92 cases
Abstract Background Malignant peritoneal mesothelioma (MPM) is a rare malignant tumor with a high mortality rate and extremely poor prognosis. In-depth pathological analysis is essential to assess tumor biological behaviors and explore potential therapeutic targets of MPM. Nucleoplasmin 2 (NPM2) is...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-10-01
|
| Series: | World Journal of Surgical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12957-022-02811-y |
| _version_ | 1811335379705397248 |
|---|---|
| author | He-liang Wu Zhi-ran Yang Yan-dong Su Ru Ma Xue-mei Du Ying Gao Yan Li |
| author_facet | He-liang Wu Zhi-ran Yang Yan-dong Su Ru Ma Xue-mei Du Ying Gao Yan Li |
| author_sort | He-liang Wu |
| collection | DOAJ |
| description | Abstract Background Malignant peritoneal mesothelioma (MPM) is a rare malignant tumor with a high mortality rate and extremely poor prognosis. In-depth pathological analysis is essential to assess tumor biological behaviors and explore potential therapeutic targets of MPM. Nucleoplasmin 2 (NPM2) is a molecular chaperone that binds histones and may play a key role in the development and progression of tumors. This study aimed to analyze the correlation between the expression level of NPM2 and the main clinicopathological characteristics and prognosis of MPM. Methods Ninety-two postoperative specimens from MPM patients following cytoreductive surgery were collected. Postoperative specimens were stained with immunohistochemistry. The expression level of NPM2 was quantitatively analyzed by QuPath-0.3.2 software. Univariate and multivariate analyses were conducted to investigate the correlation between NPM2 expression and other conventional clinicopathological characteristics. Results Among the 92 MPM patients, there were 47 males (48.9%) and 45 females (51.1%), with a median age of 56 (range: 24–73). There were 70 (76.0%) cases with loss of NPM2 protein expression, 11 (12.0%) cases with low expression, and 11 (12.0%) cases with high expression. Univariate analysis showed that NPM2 protein expression level (negative vs. low expression vs. high expression) was negatively correlated with the following three clinicopathological factors: completeness of cytoreduction (CC) score, vascular tumor emboli, and serious adverse events (SAEs) (all P < 0.05). Multivariate analysis showed that NPM2 protein expression level (negative vs. low expression vs. high expression) was independently negatively correlated with the following two clinicopathological factors: CC score [odds ratio (OR) = 0.317, 95% CI: 0.317–0.959, P = 0.042] and vascular tumor emboli (OR = 0.092, 95% CI = 0.011–0.770, P = 0.028). Survival analysis showed that loss of NPM2 protein expression (negative vs. positive) was associated with poor prognosis of MPM. Conclusions Loss of NPM2 expression is a potential immunohistochemical marker for MPM. |
| first_indexed | 2024-04-13T17:23:15Z |
| format | Article |
| id | doaj.art-80a16d7024444059bb395191de21e02a |
| institution | Directory Open Access Journal |
| issn | 1477-7819 |
| language | English |
| last_indexed | 2024-04-13T17:23:15Z |
| publishDate | 2022-10-01 |
| publisher | BMC |
| record_format | Article |
| series | World Journal of Surgical Oncology |
| spelling | doaj.art-80a16d7024444059bb395191de21e02a2022-12-22T02:37:54ZengBMCWorld Journal of Surgical Oncology1477-78192022-10-012011910.1186/s12957-022-02811-yLoss of NPM2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma: a single-center study of 92 casesHe-liang Wu0Zhi-ran Yang1Yan-dong Su2Ru Ma3Xue-mei Du4Ying Gao5Yan Li6Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Peking University Ninth School of Clinical MedicineDepartment of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical UniversityDepartment of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical UniversityDepartment of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical UniversityDepartment of Pathology, Beijing Shijitan Hospital, Capital Medical UniversityDepartment of Pathology, Beijing Shijitan Hospital, Capital Medical UniversityDepartment of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Peking University Ninth School of Clinical MedicineAbstract Background Malignant peritoneal mesothelioma (MPM) is a rare malignant tumor with a high mortality rate and extremely poor prognosis. In-depth pathological analysis is essential to assess tumor biological behaviors and explore potential therapeutic targets of MPM. Nucleoplasmin 2 (NPM2) is a molecular chaperone that binds histones and may play a key role in the development and progression of tumors. This study aimed to analyze the correlation between the expression level of NPM2 and the main clinicopathological characteristics and prognosis of MPM. Methods Ninety-two postoperative specimens from MPM patients following cytoreductive surgery were collected. Postoperative specimens were stained with immunohistochemistry. The expression level of NPM2 was quantitatively analyzed by QuPath-0.3.2 software. Univariate and multivariate analyses were conducted to investigate the correlation between NPM2 expression and other conventional clinicopathological characteristics. Results Among the 92 MPM patients, there were 47 males (48.9%) and 45 females (51.1%), with a median age of 56 (range: 24–73). There were 70 (76.0%) cases with loss of NPM2 protein expression, 11 (12.0%) cases with low expression, and 11 (12.0%) cases with high expression. Univariate analysis showed that NPM2 protein expression level (negative vs. low expression vs. high expression) was negatively correlated with the following three clinicopathological factors: completeness of cytoreduction (CC) score, vascular tumor emboli, and serious adverse events (SAEs) (all P < 0.05). Multivariate analysis showed that NPM2 protein expression level (negative vs. low expression vs. high expression) was independently negatively correlated with the following two clinicopathological factors: CC score [odds ratio (OR) = 0.317, 95% CI: 0.317–0.959, P = 0.042] and vascular tumor emboli (OR = 0.092, 95% CI = 0.011–0.770, P = 0.028). Survival analysis showed that loss of NPM2 protein expression (negative vs. positive) was associated with poor prognosis of MPM. Conclusions Loss of NPM2 expression is a potential immunohistochemical marker for MPM.https://doi.org/10.1186/s12957-022-02811-yMalignant peritoneal mesotheliomaNucleoplasmin 2QuPath softwareImmunohistochemistryPrognosis |
| spellingShingle | He-liang Wu Zhi-ran Yang Yan-dong Su Ru Ma Xue-mei Du Ying Gao Yan Li Loss of NPM2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma: a single-center study of 92 cases World Journal of Surgical Oncology Malignant peritoneal mesothelioma Nucleoplasmin 2 QuPath software Immunohistochemistry Prognosis |
| title | Loss of NPM2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma: a single-center study of 92 cases |
| title_full | Loss of NPM2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma: a single-center study of 92 cases |
| title_fullStr | Loss of NPM2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma: a single-center study of 92 cases |
| title_full_unstemmed | Loss of NPM2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma: a single-center study of 92 cases |
| title_short | Loss of NPM2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma: a single-center study of 92 cases |
| title_sort | loss of npm2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma a single center study of 92 cases |
| topic | Malignant peritoneal mesothelioma Nucleoplasmin 2 QuPath software Immunohistochemistry Prognosis |
| url | https://doi.org/10.1186/s12957-022-02811-y |
| work_keys_str_mv | AT heliangwu lossofnpm2expressionisapotentialimmunohistochemicalmarkerformalignantperitonealmesotheliomaasinglecenterstudyof92cases AT zhiranyang lossofnpm2expressionisapotentialimmunohistochemicalmarkerformalignantperitonealmesotheliomaasinglecenterstudyof92cases AT yandongsu lossofnpm2expressionisapotentialimmunohistochemicalmarkerformalignantperitonealmesotheliomaasinglecenterstudyof92cases AT ruma lossofnpm2expressionisapotentialimmunohistochemicalmarkerformalignantperitonealmesotheliomaasinglecenterstudyof92cases AT xuemeidu lossofnpm2expressionisapotentialimmunohistochemicalmarkerformalignantperitonealmesotheliomaasinglecenterstudyof92cases AT yinggao lossofnpm2expressionisapotentialimmunohistochemicalmarkerformalignantperitonealmesotheliomaasinglecenterstudyof92cases AT yanli lossofnpm2expressionisapotentialimmunohistochemicalmarkerformalignantperitonealmesotheliomaasinglecenterstudyof92cases |